Company: GANX
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001558370-25-011220
Chunk: 2

Company: Gain Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 328,327Total noncurrent liabilities​​​ 940,886​​ 872,989Total liabilities ​$ 6,137,930​$ 4,784,310​​​​​​​​Stockholders’ equity ​   ​   Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of June 30, 2025 and December 31, 2024​​$ —​$ —Common stock, $0.0001 par value: 100,000,000 shares authorized; 30,771,321 and 27,132,588 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively ​  3,078​  2,713Additional paid-in capital ​  94,642,942​  88,779,318Accumulated other comprehensive loss ​  584,083​  (247,549)Accumulated deficit ​  (81,194,908)​  (60,783,717)Loss of the period ​  (10,339,145)​  (20,411,191)Total stockholders’ equity ​​ 3,696,050​​ 7,339,574Total liabilities and stockholders’ equity ​$ 9,833,980​$ 12,123,884

​

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

​